TIS tissue therapies limited

australia's next csl?, page-24

  1. 1,057 Posts.
    ok, at the risk of being annoying with all these posts, i have reworked the numbers.

    People with diabetes
    - US: 26m
    - EU: 55m
    - RoW: 204m

    People with venous ulcers:
    - 1% of population

    Market Size

    - US chronic diabetic ulcer market size: 1b
    - EU chronic diabetic ulcer market size: 1.7b
    - Rest of World chronic ulcer market size: 2b
    - US chronic venous ulcer market size: 2.6b
    - EU chronic venous ulcer market size: 1.2b
    - Rest of World chronic ulcer market size: 5.7b
    - Total market size: 14b

    Revenues to TIS:

    - US diabetic ulcer: 16.5m
    - EU diabetic ulcer: 10.4m
    - RoW diabetic ulcer: 20.4m
    - US venous ulcer: 12.4m
    - EU venous ulcer: 25.5m
    - RoW venous ulcer: 57m
    - Total revenue: 143m

    From here you can work out your own share price using PE, DCF or whatever.

    Calculation Inputs:

    1. Diabetic Ulcer calculations: an estimate of the number of people with chronic diabetic ulcers (based on 10% of people with diabetes having ulcers and of those 50% having chronic ulcers) and revenues to TIS based on 10% market share and 10% royalties

    2. Venous ulcer calculations: an estimate of the number of people with chronic venous ulcers (based on 1% of population having ulcers and 50% of those having chronic ulcers) and revenues to TIS based on 10% market share and 10% royalties

    3. Price: I assumed USD800 per treatment for the US, USD600 for EU and 200 for RoW.


    Further comments:

    1. Where these calculations are questionable:
    - price charged for VitroGro
    - estimates of venous ulcers
    - TIS royalties
    - TIS getting 10% of the chronic ulcer market

    2. From what i have read about the history of products like Dermagraft, the partner is very important. Dermagraft went nowhere under S&N. Last year under new management it had 150m in sales (almost a 805 increase yoy). I for one an happy that management are fighting for the best deal and hopefully being picky about who they do the deal with.

    3. I cant get to 6 dollars EPS but still, pretty good.

    4. I am happy to share my calculation spreadsheet. If anyone knows how to post a spreadsheet here or wants to do it for me, post your email address, ill send it to you and you can post it back here for others.

    5. Again, i don't expect these calculations to ever be proven correct. I do these simply to create a rough idea of what the value might be at some stage in the future if a list of things go our way.

    6. Don't invest based on what i have provided here. But by all means pick it apart and tell me what i am wrong.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.